ES2177316T3 - Anticuerpos humanos antifacotores ix/ixa. - Google Patents

Anticuerpos humanos antifacotores ix/ixa.

Info

Publication number
ES2177316T3
ES2177316T3 ES99943928T ES99943928T ES2177316T3 ES 2177316 T3 ES2177316 T3 ES 2177316T3 ES 99943928 T ES99943928 T ES 99943928T ES 99943928 T ES99943928 T ES 99943928T ES 2177316 T3 ES2177316 T3 ES 2177316T3
Authority
ES
Spain
Prior art keywords
ixa
fix
human antibodies
antifacotor
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99943928T
Other languages
English (en)
Inventor
Camellia W Adams
Brigitte Devaux
Dan L Eaton
Philip E Hass
J Kevin Judice
Daniel Kirchhofer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2177316T3 publication Critical patent/ES2177316T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere al aislamiento, identificación, síntesis, expresión y purificación de anticuerpos que reaccionan con el factor IX (FIX)/factor IXa (FIXa), y especialmente con el dominio Gla de FIX/FIXa. En aspectos particulares, la invención proporciona anticuerpos humanos que reaccionan con el dominio Gla de FIX/FIXa humano. La invención se refiere además a composiciones, especialmente composiciones farmacéuticas, artículos de fabricación, y procedimientos para inhibir la actividad del FIX/FIXa, e inhibir la coagulación dependiente del FIX/FIXa.
ES99943928T 1998-08-28 1999-08-26 Anticuerpos humanos antifacotores ix/ixa. Expired - Lifetime ES2177316T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9823398P 1998-08-28 1998-08-28
US12276799P 1999-03-03 1999-03-03

Publications (1)

Publication Number Publication Date
ES2177316T3 true ES2177316T3 (es) 2002-12-01

Family

ID=26794469

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99943928T Expired - Lifetime ES2177316T3 (es) 1998-08-28 1999-08-26 Anticuerpos humanos antifacotores ix/ixa.

Country Status (15)

Country Link
US (3) US6624295B1 (es)
EP (1) EP1107996B1 (es)
JP (1) JP4638035B2 (es)
CN (1) CN1183160C (es)
AT (1) ATE217889T1 (es)
AU (1) AU766551C (es)
BR (1) BR9913435A (es)
CA (1) CA2341276C (es)
DE (1) DE69901569T2 (es)
DK (1) DK1107996T3 (es)
ES (1) ES2177316T3 (es)
IL (1) IL140917A0 (es)
NZ (1) NZ509430A (es)
PT (1) PT1107996E (es)
WO (1) WO2000012562A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE0000675D0 (sv) * 2000-03-02 2000-03-02 Protease Ab Monoclonal antibodies
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
BR0015872A (pt) * 2000-05-15 2004-08-03 Smithkline Beecham Corp Agentes antitrombóticos
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
DE502006008613D1 (de) * 2006-09-22 2011-02-10 Wacker Chemie Ag Verfahren zur fermentativen Herstellung von Proteinen
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
RU2590726C2 (ru) * 2010-03-30 2016-07-10 Октафарма Аг Способ очистки витамин к-зависимых белков, таких как коагуляционный фактор ix
DK2552948T3 (en) 2010-03-30 2016-10-17 Octapharma Ag A process for the purification of the protein growth factor G-CSF
ES2755398T3 (es) * 2010-04-13 2020-04-22 Medimmune Llc Andamios multiméricos específicos de TRAIL R2
JP6016789B2 (ja) * 2011-05-23 2016-10-26 積水メディカル株式会社 Ｐｉｖｋａ−ｉｉ測定試薬における非特異反応の抑制方法
JP2018527350A (ja) * 2015-09-01 2018-09-20 イミュンワーク インク．Ｉｍｍｕｎｗｏｒｋ Ｉｎｃ． 血餅形成の予防及び／又は血栓症の治療のための分子構築物
KR102702288B1 (ko) * 2016-12-23 2024-09-05 노파르티스 아게 항-인자 XI/XIa 항체를 사용한 치료 방법
CN110248964B (zh) 2017-02-01 2024-08-27 诺和诺德股份有限公司 促凝血抗体
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体
CN116333145B (zh) * 2023-04-14 2023-11-07 北京基科晟斯医药科技有限公司 结合活化凝血因子ix的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720983A1 (de) * 1987-06-25 1989-01-05 Hoechst Ag Immunometrisches bestimmungsverfahren
AU7766391A (en) 1990-04-23 1991-11-11 Corvas International N.V. Thrombus-specific antibody derivatives
DE69427928T3 (de) 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
MX9504802A (es) 1994-03-17 1997-05-31 Merck Patent Gmbh Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
JP2002523081A (ja) 2002-07-30
CN1183160C (zh) 2005-01-05
CN1317015A (zh) 2001-10-10
US7049411B2 (en) 2006-05-23
EP1107996B1 (en) 2002-05-22
AU5692399A (en) 2000-03-21
CA2341276A1 (en) 2000-03-09
BR9913435A (pt) 2001-09-25
WO2000012562A1 (en) 2000-03-09
DE69901569T2 (de) 2002-12-19
CA2341276C (en) 2005-10-11
JP4638035B2 (ja) 2011-02-23
ATE217889T1 (de) 2002-06-15
EP1107996A1 (en) 2001-06-20
US7354585B2 (en) 2008-04-08
NZ509430A (en) 2002-04-26
AU766551B2 (en) 2003-10-16
US6624295B1 (en) 2003-09-23
US20060088534A1 (en) 2006-04-27
PT1107996E (pt) 2002-10-31
AU766551C (en) 2005-02-17
US20060193851A1 (en) 2006-08-31
DK1107996T3 (da) 2002-09-16
IL140917A0 (en) 2002-02-10
DE69901569D1 (de) 2002-06-27

Similar Documents

Publication Publication Date Title
ES2177316T3 (es) Anticuerpos humanos antifacotores ix/ixa.
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
ATE376026T1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
MXPA03005273A (es) Anticuerpos producidos procarioticamente y sus usos.
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
CY1109984T1 (el) Παραλλαγες gla πεδιου παραγοντα vii ή viia
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
ATE494275T1 (de) Herstellung von cis-pellitorin und verwendung als aromastoff
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DK1200418T3 (da) Nematodicide trifluorbutener
SE9802729D0 (sv) Novel Compounds
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
GB0111186D0 (en) Novel compounds
CY1109995T1 (el) Συνθεσεις περιεχουσες προϊοντα σογιας
SE9802937D0 (sv) Novel compounds
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
BRPI0415285A (pt) derivados de aminoalcanol
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri